These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32224020)

  • 1. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
    Kakkis E; Marsden D
    Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.
    Jones SA; Marsden D; Koutsoukos T; Sniadecki J; Tylee K; Phillippo S; Kakkis E
    Mol Genet Metab; 2020 Aug; 130(4):255-261. PubMed ID: 32563631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
    Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
    Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separation of sulfated urinary glycosaminoglycans by high-resolution electrophoresis for isotyping of mucopolysaccharidoses in Malaysia.
    Nor A; Zabedah MY; Norsiah MD; Ngu LH; Suhaila AR
    Malays J Pathol; 2010 Jun; 32(1):35-42. PubMed ID: 20614724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses.
    Hochuli M; Wüthrich K; Steinmann B
    NMR Biomed; 2003 Jun; 16(4):224-36. PubMed ID: 14558120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mucopolysaccharidosis: clinical features, diagnosis and management].
    Suarez-Guerrero JL; Gómez Higuera PJ; Arias Flórez JS; Contreras-García GA
    Rev Chil Pediatr; 2016; 87(4):295-304. PubMed ID: 26613630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
    Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
    Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and II clinical trials for the mucopolysaccharidoses.
    Poswar F; Baldo G; Giugliani R
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1331-1340. PubMed ID: 29065735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A glycomic workflow for LC-MS/MS analysis of urine glycosaminoglycan biomarkers in mucopolysaccharidoses.
    Nilsson J; Persson A; Vorontsov E; Nikpour M; Noborn F; Larson G; Blomqvist M
    Glycoconj J; 2023 Oct; 40(5):523-540. PubMed ID: 37462780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
    Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
    J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
    Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of mucopolysaccharidoses.
    Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
    Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses.
    Chuang CK; Lin HY; Wang TJ; Tsai CC; Liu HL; Lin SP
    Orphanet J Rare Dis; 2014 Sep; 9():135. PubMed ID: 25178307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.
    Byers S; Rozaklis T; Brumfield LK; Ranieri E; Hopwood JJ
    Mol Genet Metab; 1998 Dec; 65(4):282-90. PubMed ID: 9889015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique medical issues in adult patients with mucopolysaccharidoses.
    Mitchell J; Berger KI; Borgo A; Braunlin EA; Burton BK; Ghotme KA; Kircher SG; Molter D; Orchard PJ; Palmer J; Pastores GM; Rapoport DM; Wang RY; White K
    Eur J Intern Med; 2016 Oct; 34():2-10. PubMed ID: 27296591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy: efficacy and limitations.
    Concolino D; Deodato F; Parini R
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):120. PubMed ID: 30442189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.
    Peck SH; Casal ML; Malhotra NR; Ficicioglu C; Smith LJ
    Mol Genet Metab; 2016 Aug; 118(4):232-43. PubMed ID: 27296532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.
    Fox JE; Volpe L; Bullaro J; Kakkis ED; Sly WS
    Mol Genet Metab; 2015 Feb; 114(2):203-8. PubMed ID: 25468648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.